Related Experiment Video
Updated: Jul 5, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT
Maryna Skliut1, Dara G Jamieson
1New York - Presbyterian Hospital, Weill Medical College of Cornell University, Department of Neurology and Neuroscience, 525 East 68th Street, Suite F-610, New York, NY 10021, USA.
Current Cardiology Reports
|April 18, 2008
Summary
For secondary stroke prevention, aspirin plus extended-release dipyridamole offers benefits over monotherapy. However, aspirin plus clopidogrel does not show added benefit and increases bleeding risks.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Secondary prevention of ischemic stroke and transient ischemic attack (TIA) relies on risk factor modification.
- Atherothrombotic disease, involving platelet activation and aggregation, underlies most noncardioembolic ischemic strokes.
- Antiplatelet medications are crucial for secondary stroke prevention in arterial disease.
Purpose of the Study:
- To review recent studies on antiplatelet medications for secondary stroke prevention.
- To discuss the efficacy and controversies surrounding combination antiplatelet therapy.
Main Methods:
- Review of recent clinical studies and trials on antiplatelet agents.
- Analysis of combination therapies including aspirin with extended-release dipyridamole or clopidogrel.
Main Results:
- Aspirin plus extended-release dipyridamole demonstrated additive benefits compared to monotherapy.
- Aspirin plus clopidogrel did not show superior efficacy in preventing recurrent ischemic stroke over individual agents.
- Combination therapy with aspirin and clopidogrel increased the risk of hemorrhagic side effects.
Conclusions:
- Combination antiplatelet therapy requires careful consideration of risks and benefits.
- Aspirin plus extended-release dipyridamole is a viable option for secondary stroke prevention.
- Further research is needed to clarify optimal antiplatelet strategies and address existing controversies.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...